Electromed (ELMD) Q2 2025 earnings summary

Executive summary

• Achieved record quarterly revenue of $16.3 million, up 18.7% year-over-year, marking the ninth consecutive quarter of year-over-year growth in both revenue and net income, driven by strong performance across all customer categories and sales force expansion.

• Net income reached $2.0 million ($0.22 per diluted share), up from $1.67 million in the prior year, with operating income at $2.5 million and gross margin improving to 77.7%.

• Stock price has appreciated significantly over the past six and twelve months.

• Strategic investments included a new CRM system and the “Triple Down on Bronchiectasis” campaign, engaging over 10,000 clinicians.

Financial highlights

• Net revenues grew 18.7% year-over-year to $16.3 million for the quarter and $30.9 million for six months; gross profit increased to $12.6 million (77.7% margin).

• SG&A expenses rose 20.3% to $9.8 million, mainly due to higher compensation and increased headcount.

• Pre-tax income was $2.7 million, with record quarterly EPS of $0.22 per diluted share.

• Operating cash flow for the six months was $5.5 million, with cash and cash equivalents at $16.2 million and no debt as of December 31, 2024.

• Share repurchases totaled approximately $4.54 million under the $5 million authorization.

Outlook and guidance

• Focus remains on delivering double-digit top-line growth and expanded operating leverage for the full year, with management expecting continued improvements supported by ongoing investments in sales and operational efficiency.

• Management expects current working capital and available credit to be sufficient for operational and capital needs for at least the next twelve months.

• Cash, cash equivalents, and cash flows from operations are expected to meet requirements for fiscal 2025 and the foreseeable future.